Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933248 | 0.79 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL20579813 | 0.78 | CA1 (0.41) | CA1CYP1A2BLMLTA4HRNPEP | |
| SCHEMBL108022 | 0.76 | CA1 (0.48) | CA1CYP1A2BLMTRPA1LTA4H | |
| SCHEMBL12991448 | 0.76 | ALDH1A1 (0.42) | — | |
| SCHEMBL14403217 | 0.74 | CA1 (0.46) | CA1CYP1A2BLMTRPA1LTA4H | |
| SCHEMBL14219264 | 0.73 | — | — | |
| SCHEMBL800723 | 0.72 | CA1 (0.55) | CA1CYP1A2BLMTRPA1 | |
| SCHEMBL9618592 | 0.71 | CA1 (0.43) | CA1CYP1A2BLMTRPA1 | |
| SCHEMBL24253185 | 0.71 | NAMPT (0.42) | CYP1A2BLMKDM4CKDM4APHF8 | |
| SCHEMBL17667791 | 0.70 | CA1 (0.41) | CA1CYP1A2BLMTRPA1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054623-A1 | Lipo-Conjugation of Peptides | NEOSE TECHNOLOGIES, INC. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054623-A1 | Lipo-Conjugation of Peptides | PTMS, LYPLA1, LPCAT3 | CA1 3958/4885CYP1A2 4726/4885BLM 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.